Improvement in health-related quality of life after therapy with omeprazole in patients with coronary artery disease and recurrent angina-like chest pain. A double-blind, placebo-controlled trial of the SF-36 survey

Health and Quality of Life Outcomes

Volumn 9, Issue , 2011, Pages

  Budzyński, Jacek ^a,b   Pulkowski, Grzegorz ^b   Suppan, Karol ^b   Fabisiak, Jacek ^b   Majer, Marcin ^b   Kłopocka, Maria ^a   Galus Pulkowska, Beata ^c   Wasielewski, Marcin ^b  

^a NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^b Dr Jan Biziel University Hospital No 2   (Poland)

^c General Practice   (Poland)

Author keywords

Chest painome; Coronary artery disease; Prazole; Quality of lifeSF 36 questionnaire

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; GLYCERYL TRINITRATE; NITRATE; OMEPRAZOLE; PLACEBO; ANTIULCER AGENT;

ADULT; ANGIOGRAPHY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; MALE; MENTAL HEALTH; QUALITY OF LIFE; QUESTIONNAIRE; SHORT FORM 36; THORAX PAIN; AGED; ANGINA PECTORIS; ANGIOCARDIOGRAPHY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; MIDDLE AGED; RADIOGRAPHY; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; TREATMENT OUTCOME;

ADULT; AGED; ANGINA PECTORIS; ANTI-ULCER AGENTS; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; OMEPRAZOLE; PLACEBOS; QUALITY OF LIFE; QUESTIONNAIRES; RECURRENCE; TREATMENT OUTCOME;

EID: 80053172188     PISSN: None     EISSN: 14777525     Source Type: Journal    
DOI: 10.1186/1477-7525-9-77     Document Type: Article

References (44)

1. El-Dika S, Guyatt GH, Armstrong D, Degl'innocenti A, Wiklund I, Fallone CA, Tanser L, Veldhuyzen van Zanten S, Heels-Ansdell D, Wahlqvist P, Chiba N, Barkun AN, Austin P, Schünemann HJ. The impact of illness in patients with moderate to severe gastro-esophageal reflux disease. BMC Gastroenterol 2005, 5:23.
2. Höfer S, Kullich W, Graninger U, Wonisch M, Gassner A, Klicpera M, Laimer H, Marko C, Schwann H, Müller R. Cardiac rehabilitation in Austria: long term health-related quality of life outcomes. Health Qual Life Outcomes 2009, 7:99.
3. Ware JE, Kosinski M, Gandek B. SF-36 Health Survey Manual & Interpretation Guide. Lincoln, QualityMetric Inc 2004,
4. van Rossum LG, Laheij RJ, Vlemmix F, Jansen JB, Verheugt FW. Health-related quality of life in patients with cardiovascular disease- the effect of upper gastrointestinal symptom treatment. Aliment Pharmacol Ther 2004, 19:1099-104.
5. Jax TW, Peters AJ, Khattab AA, Heintzen MP, Schoebel FC. Percutaneous coronary revascularization in patients with formerly "refractory angina pectoris in end-stage coronary artery disease"-not "end-stage" after all. BMC Cardiovasc Disord 2009, 9:42.
6. Beltrame JF, Weekes AJ, Morgan C, Tavella R, Spertus JA. The prevalence of weekly angina among patients with chronic stable angina in primary care practices: The Coronary Artery Disease in General Practice (CADENCE) Study. Arch Intern Med 2009, 169:1491-9.
7. Arnold SV, Morrow DA, Lei Y, Cohen DJ, Mahoney EM, Braunwald E, Chan PS. Economic impact of angina after an acute coronary syndrome: insights from the MERLIN-TIMI 36 trial. Circ Cardiovasc Qual Outcomes 2009, 2:344-53.
8. Throndson K, Sawatzky JA. Angina following percutaneous coronary intervention: in-stent restenosis. Can J Cardiovasc Nurs 2009, 19:16-23.
9. Phan A, Shufelt C, Merz CN. Persistent chest pain and no obstructive coronary artery disease. JAMA 2009, 301:1468-74.
10. Dobrzycki S, Baniukiewicz A, Korecki J, Bachórzewska-Gajewska H, Prokopczuk P, Musiał WJ, Kamiński KA, Da{ogonek}browski A. Does gastro-esophageal reflux provoke the myocardial ischemia in patients with CAD?. Int J Cardiol 2005, 104:67-72.
11. Budzyński J, Kłopocka M, Pulkowski G, Suppan K, Fabisiak J, Majer M, a{ogonek}wia{ogonek}tkowski M. The effect of double dose of omeprazole on the course of angina pectoris and treadmill stress test in patients with coronary artery disease-a randomised, double-blind, placebo controlled, crossover trial. Int J Cardiol 2008, 127:233-9.
12. Husser D, Bollmann A, Kühne C, Molling J, Klein HU. Evaluation of noncardiac chest pain: diagnostic approach, coping strategies and quality of life. Eur J Pain 2006, 10:51-5.
13. Dickman R, Mattek N, Holub J, Peters D, Fass R. Prevalence of upper gastrointestinal tract findings in patients with noncardiac chest pain versus those with gastroesophageal reflux disease (GERD)-related symptoms: results from a national endoscopic database. Am J Gastroenterol 2007, 102:1173-9.
14. Dickman R, Fass R. Noncardiac chest pain. Clin Gastroenterol Hepatol 2006, 4:558-63.
15. Laheij RJ, Van Rossum LG, Krabbe PF, Jansen JB, Verheugt FW. The impact of gastrointestinal symptoms on health status in patients with cardiovascular disease. Aliment Pharmacol Ther 2003, 17:881-5.
16. Budzyński J, Pulkowski G, Kłopocka M, Augustyńska B, Sinkiewicz A, Fabisiak J, Suppan K, Majer M, Świa{ogonek}tkowski M. The treatment with double dose of omeprazole increases in beta-endorphin plasma level in patients with coronary artery disease. Archives of Medical Science 2010, 6:201-207.
17. Świa{ogonek}tkowski M, Budzyński J, Kłopocka M, Pulkowski G, Suppan K, Fabisiak J, Morawski W, Majer M. Suppression of gastric acid production may improve the course of angina pectoris and the results of treadmill stress test in patients with coronary artery disease. Med Sci Monit 2004, 10:CR524-9.
18. Chauhan A, Mullins PA, Taylor G, Petch MC, Schofield PM. Cardioesophageal reflex: a mechanism for "linked angina" in patients with angiographically proven coronary artery disease. J Am Coll Cardiol 1996, 27:1621-8.
19. Budzyński J. Does esophageal dysfunction affect the course of treadmill stress tests in patients with recurrent angina-like chest pain?. Pol Arch Med Wewn 2010, 12:484-489.
20. Hsiao FY, Tsai YW, Huang WF, Wen YW, Chen PF, Chang PY, Kuo KN. A comparison of aspirin and clopidogrel with or without proton pump inhibitors for the secondary prevention of cardiovascular events in patients at high risk for gastrointestinal bleeding. Clin Ther 2009, 31:2038-47.
21. Bovenschen HJ, Laheij RJ, Tan AC, Witteman EM, Rossum LG, Jansen JB. Health-related quality of life of patients with gastrointestinal symptoms. Aliment Pharmacol Ther 2004, 20:311-9.
22. Kato M, Watanabe M, Konishi S, Kudo M, Konno J, Meguro T, Kitamori S, Nakagawa S, Shimizu Y, Takeda H, Asaka M. Randomized, double-blind, placebo-controlled crossover trial of famotidine in patients with functional dyspepsia. Aliment Pharmacol Ther 2005, 21(Suppl 2):27-31.
23. Björnsson E, Abrahamsson H, Simrén M, Mattsson N, Jensen C, Agerforz P, Kilander A. Discontinuation of proton pump inhibitors in patients on long-term therapy: a double-blind, placebo-controlled trial. Aliment Pharmacol Ther 2006, 24:945-54.
24. Johanson JF, Siddique R, Damiano AM, Jokubaitis L, Murthy A, Bhattacharjya A. Rabeprazole improves health-related quality of life in patients with erosive gastroesophageal reflux disease. Dig Dis Sci 2002, 47:2574-8.
25. Revicki DA, Zodet MW, Joshua-Gotlib S, Levine D, Crawley JA. Health-related quality of life improves with treatment-related GERD symptom resolution after adjusting for baseline severity. Health Qual Life Outcomes 2003, 1:73.
26. Kalaitzakis E, Björnsson E. A review of esomeprazole in the treatment of gastroesophageal reflux disease (GERD). Ther Clin Risk Manag 2007, 3:653-63.
27. Hiyama T, Matsuo K, Urabe Y, Fukuhara T, Tanaka S, Yoshihara M, Haruma K, Chayama K. Meta-analysis used to identify factors associated with the effectiveness of proton pump inhibitors against non-erosive reflux disease. J Gastroenterol Hepatol 2009, 24:1326-32.
28. Degl' Innocenti A, Guyatt GH, Wiklund I, Heels-Ansdell D, Armstrong D, Fallone CA, Tanser L, van Zanten SV, El-Dika S, Chiba N, Barkun AN, Austin P, Schünemann HJ. The influence of demographic factors and health-related quality of life on treatment satisfaction in patients with gastroesophageal reflux disease treated with esomeprazole. Health Qual Life Outcomes 2005, 3:4.
29. Yoshida S, Nii M, Date M. Effects of omeprazole on symptoms and quality of life in Japanese patients with reflux esophagitis: Final results of OMAREE, a large-scale clinical experience investigation. BMC Gastroenterol 2011, 11:15.
30. Littner MR, Leung FW, Ballard ED, Huang B, Samra NK, . Lansoprazole Asthma Study Group Effects of 24 weeks of lansoprazole therapy on asthma symptoms, exacerbations, quality of life, and pulmonary function in adult asthmatic patients with acid reflux symptoms. Chest 2005, 128:1128-35. Lansoprazole Asthma Study Group.
31. Wo JM, Koopman J, Harrell SP, Parker K, Winstead W, Lentsch E. Double-blind, placebo-controlled trial with single-dose pantoprazole for laryngopharyngeal reflux. Am J Gastroenterol 2006, 101:1972-8.
32. Hawkey CJ, Svedberg LE, Naesdal J, Byrne C. Esomeprazole for the management of upper gastrointestinal symptoms in patients who require NSAIDs: a review of the NASA and SPACE double-blind, placebo-controlled studies. Clin Drug Investig 2009, 29:677-87.
33. Reimer C, Søndergaard B, Hilsted L, Bytzer P. Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy. Gastroenterology 2009, 137:80-7.
34. Glise H, Hallerbäck B, Wiklund I. Quality of life: a reflection of symptoms and concerns. Scand J Gastroenterol Suppl 1996, 221:14-7.
35. Rollman BL, Belnap BH, LeMenager MS, Mazumdar S, Houck PR, Counihan PJ, Kapoor WN, Schulberg HC, Reynolds CF. Telephone-delivered collaborative care for treating post-CABG depression: a randomized controlled trial. JAMA 2009, 302:2095-103.
36. Rey E, Alvarez-Sánchez A, Rodríguez-Artalejo F, Moreno Elola-Olaso C, Almansa C, Díaz-Rubio M. Onset and disappearance rates of gastroesophageal reflux symptoms in the Spanish population, and their impact on quality of life. Rev Esp Enferm Dig 2009, 101:477-82.
37. Juurlink DN, Gomes T, Ko DT, Szmitko PE, Austin PC, Tu JV, Henry DA, Kopp A, Mamdani MM. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009, 180:713-8.
38. Gaspar A, Ribeiro S, Nabais S, Rocha S, Azevedo P, Pereira MA, Brandāo A, Salgado A, Correia A. Proton pump inhibitors in patients treated with aspirin and clopidogrel after acute coronary syndrome. Rev Port Cardiol 2010, 29:1511-20.
39. Lima JP, Brophy JM. The potential interaction between clopidogrel and proton pump inhibitors: a systematic review. BMC Med 2010, 8:81.
40. Kasprzak M, Koziński M, Bielis L, Boinska J, Plazuk W, Marciniak A, Budzyński J, Siller-Matula J, Rość D, Kubica J. Pantoprazole may enhance antiplatelet effect of enteric-coated aspirin in patients with acute coronary syndrome. Cardiol J 2009, 16:535-44.
41. Würtz M, Grove EL, Kristensen SD, Hvas AM. The antiplatelet effect of aspirin is reduced by proton pump inhibitors in patients with coronary artery disease. Heart 2010, 96:368-71.
42. Bhatt DL, Cryer BL, Contant CF, Cohen M, Lanas A, Schnitzer TJ, Shook TL, Lapuerta P, Goldsmith MA, Laine L, Scirica BM, Murphy SA, Cannon CP, . COGENT Investigators Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 2010, 363:1909-17. COGENT Investigators.
43. Juurlink DN. Clopidogrel with or without omeprazole in coronary disease. N Engl J Med 2011, 364:681-2.
44. Modlin IM, Hunt RH, Malfertheiner P, Moayyedi P, Quigley EM, Tytgat GN, Tack J, Heading RC, Holtman G, Moss SF, . Vevey NERD Consensus Group Diagnosis and management of non-erosive reflux disease--the Vevey NERD Consensus Group. Digestion 2009, 80:74-88. Vevey NERD Consensus Group.